Beller F K
Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City.
Geburtshilfe Frauenheilkd. 1993 Oct;53(10):657-66. doi: 10.1055/s-2007-1023605.
Present literature on epidemiology shows, that estrogens administered either in the form of contraceptives or as replacement therapy will reduce the relative risk of ovarian carcinoma to less than 0.5. Likewise this result was also seen in all studies without exception. The reduction becomes manifest after four months and is maintained for many years following discontinuation. The same applies to corpus carcinoma, provided estrogens are administered concomitantly with gestagens. Administration of estrogens alone results in enhancing the relative risk up to 3-4. Hyperproliferation can lead to carcinoma of the endometrium. No data are presently available for cervical carcinoma, that would justify the assumption, that the relative risk for squamous cell carcinoma of the cervix is increased. This statement does not apply to the adenocarcinoma of the cervix, since too few cases have been studied. The following statements apply to carcinoma of the breast: OC's (oral contraceptives) taken before the age of 45 do not increase the relative risk. This is also true of females, for whom a risk factor exists, as for example family case history, period of administration, benign diseases of the breast, use of OC's before the first pregnancy, nulliparity, no breast-feeding. Possible, but not proven is a slight increase in relative risk to 1.3 in females, in whom carcinoma of the breast had been diagnosed before the age of 34. If this increase is accepted, one must likewise expect a decrease in relative risk after the age of 45. A hormonal replacement therapy for up to four years will not increase the relative risk. This applies also to replacement therapy with gestagens, even though only few data are available at present. It has been concluded from the results of some studies, that a slight increase in relative risk to 1.3 is possible after long-term therapy (more than 15 years). However, no causal relationship to cancer of the breast has been established. It has not been claimed so far, that estrogens cause cancer of the breast. Should the slight relative risk increase be confirmed, this would mean, that in a small group of very young females, estrogens may promote the growth of an already existing cancer of the breast.
目前的流行病学文献表明,以避孕药形式或作为替代疗法使用的雌激素会将卵巢癌的相对风险降低至小于0.5。同样,所有研究无一例外都得出了这一结果。这种降低在四个月后显现出来,并在停药后持续多年。对于子宫内膜癌也是如此,前提是雌激素与孕激素同时使用。单独使用雌激素会导致相对风险增加至3 - 4倍。过度增殖会导致子宫内膜癌。目前尚无关于宫颈癌的数据能证明假设宫颈鳞状细胞癌的相对风险会增加是合理的。这一说法不适用于宫颈腺癌,因为研究的病例太少。以下说法适用于乳腺癌:45岁之前服用口服避孕药不会增加相对风险。对于存在风险因素的女性也是如此,例如家族病史、服药时间、乳腺良性疾病、首次怀孕前使用口服避孕药、未生育、未哺乳。对于34岁之前被诊断出患有乳腺癌的女性,相对风险可能会轻微增加至1.3,但尚未得到证实。如果接受这种增加,那么同样必须预期45岁之后相对风险会降低。长达四年的激素替代疗法不会增加相对风险。这也适用于孕激素替代疗法,尽管目前仅有少量数据。从一些研究结果可以推断,长期治疗(超过15年)后相对风险可能会轻微增加至1.3。然而,尚未确定与乳腺癌有因果关系。到目前为止,尚未有人声称雌激素会导致乳腺癌。如果轻微的相对风险增加得到证实,这将意味着在一小部分非常年轻的女性中,雌激素可能会促进已存在的乳腺癌生长。